热门资讯> 正文
Zentalis Pharmaceuticals GAAP每股收益为-1.24美元
2024-08-09 22:09
- Zentalis Pharmaceuticals press release (NASDAQ:ZNTL): Q2 GAAP EPS of -$1.24.
- Cash, Cash Equivalents and Marketable Securities Position: As of June 30, 2024, Zentalis had cash, cash equivalents and marketable securities of $426.4 million,
More on Zentalis Pharmaceuticals
- Zentalis faces partial FDA hold on lead asset; Wedbush downgrades (update)
- Seeking Alpha’s Quant Rating on Zentalis Pharmaceuticals
- Historical earnings data for Zentalis Pharmaceuticals
- Financial information for Zentalis Pharmaceuticals
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
